GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% Solution is indicated as a replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients ≥2 years.
![GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% logo.](/content/experience-fragments/takeda/gammagard/us/en/hcp/header/master/_jcr_content/root/container_1325140548/container_6852551/container/image.coreimg.svg/1755842420057/logo-gammagard-white.svg){kind=logo}
PI Treatment Journey
PI=primary immunodeficiency.
There are several options available for treating primary immunodeficiency (PI)
GAMMAGARD LIQUID is one Takeda therapy that treats PI. Depending on your patients’ needs, an alternate therapy to GAMMAGARD LIQUID may be appropriate. The chart below highlights key details about GAMMAGARD LIQUID (in orange) and two other IG therapies to help you with your decision-making.
How GAMMAGARD LIQUID compares to other Takeda IG therapies
| GAMMAGARD LIQUID IV | SubQ IG with flexible infusion options | Once-a-month* SubQ IG infusion | |
|---|---|---|---|
| Administration options | In a vein | Under the skin | A SCIG with hyaluronidase that helps more IG to be absorbed into the bloodstream |
| Frequency | Every 3 to 4 weeks | Daily to every 2 weeks | Every 3 to 4 weeks |
| Average infusion time† | ~2 hours | ~1 to 2 hours | ~2 hours |
| Infusion time range† | ~1 to 2 hours | ~5 min to 2 hours | ~1 to 2 hours |
| Who administers | Nurse | Nurse or patient/ caregiver after appropriate training by HCP | Nurse or patient/ caregiver after appropriate training by HCP |
| Location | Home, healthcare office, hospital, or infusion center | Home, healthcare office, hospital, or infusion center | Home, healthcare office, hospital, or infusion center |
| Learn more | Learn more |
*Every 3 or 4 weeks.
†Infusion times may vary based on frequency, dose, volume, number of needlesticks, and tolerability.
Factors to Consider
Once a patient understands the different IG therapy options at a high level and how they compare to each other, there are several other factors that may lead to one option being more suitable for the patient.
To help you both make a more educated therapy decision, discuss topics such as:
| Does the patient prefer nurse-administration or self-administration? | What number of needlesticks is the patient comfortable with? |
|---|---|
| Self-administration Some patients prefer to administer on their own | More Prefer more needles in a single infusion to reduce infusion time |
| Nurse-administration Some patients may prefer assisted administration by a trained medical professional | Fewer Prefer to minimize the number of needlesticks per infusion |
| Where is the closest hospital or infusion center? | How often does the patient want to receive treatment? | How does the patient feel about duration of treatment? |
|---|---|---|
| Far If a patient lives far away from an infusion center, they may want to administer at home to avoid the long commute | Daily | More time |
Near If a patient lives close to an infusion center and prefers nurse-administration, they | Every 2 weeks | Less time |
| Monthly |
The answers to these questions will help you and your patient determine appropriate therapy options.
The Path to Treatment Guide
To help you and your PI patients discuss which IG therapy may be right for them, we’ve prepared a downloadable guide. It contains an overview of factors to consider when making a treatment decision, a summary of Takeda’s IG products including another formulation for GAMMAGARD, financial support, and information on fulfillment and resources available for patient support.
Join for updates that can help support your patient care decisions
Sign up for updates on GAMMAGARD LIQUID for PI.